Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Restless Leg Syndrome Clinical Trials

A listing of Restless Leg Syndrome medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (12) clinical trials

Patient Inclusion Criteria: Ages 18+ RLS diagnosis 15 nights or more in past month with RLS symptoms Must stop all RLS medications 2 weeks prior No Horizant usage in past Men or women 18 years of age or older History of RLS symptoms for at least 15 nights/month Documented RLS ...

Phase

Patient Inclusion Criteria: Ages 18-60 SPMS diagnosis Must be able to walk Diagnosed with MS as defined by the modified McDonald criteria SPMS defined as relapsing-remitting disease with recent progression in MS-related neurological deficits EDSS score 3.0 - 6.0, inclusively Presence of myelin reactive T-cells Patient Exclusion Criteria: Diagnosed with ...

Phase

If you're experiencing symptoms of Restless Legs Syndrome (RLS), learn more about this medical research study of an investigational RLS drug. Local doctors are currently conducting the CONCORD medical research study of a Restless Legs Syndrome (RLS) study drug. They want to evaluate an approved dose strength with two investigational ...

Phase N/A

The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin) versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome.

Phase

Pilot Study: Randomized Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)

The restless legs syndrome (RLS) (also known as Willis Ekbom Disease) occurs in about 1/3rd of patients with iron deficiency anemia (IDA). Treatment correcting the IDA is expected to also be effective for reducing or eliminating the RLS with IDA. Two accepted treatments for IDA (oral ferrous sulfate, intravenous ferumoxytol) ...

Phase

An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

The primary objective of the trial is to evaluate the efficacy of HORIZANT 300 mg and 600 mg, compared to placebo, at 12 weeks of treatment, for the treatment of Restless Legs Syndrome (RLS) in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe primary RLS.

Phase

A Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

The primary objective is to assess the pharmacokinetics (PK) of gabapentin following the single-dose administration of HORIZANT (Gabapentin Enacarbil) in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe Primary Restless Legs Syndrome (RLS).

Phase

An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT (Gabapentin Enacarbil) 600 mg daily, for the treatment of RLS in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe primary RLS.

Phase

Randomized Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

This will be a Phase II, randomized, placebo-controlled study. All subjects who meet the inclusion criteria, with no exclusion criteria, will qualify to enter the Screening Phase. The study will enroll 70 eligible subjects to receive blinded study drug in Treatment Phase I. All eligible subjects will be randomized in ...

Phase

Specified Drug Use-Results Survey of Regnite

Sleeping condition and severity of restless legs syndrome (RLS) were recorded at the start and during the treatment. The treatment period is scheduled to last 52 weeks in principle. For patients completing or discontinuing the use of Regnite® within 52 weeks, follow up on the withdrawal and rebound syndrome will ...

Phase N/A